An update on larynx cancer

Ca-A Cancer Journal for Clinicians - Tập 67 Số 1 - Trang 31-50 - 2017
Conor Steuer1, Mark W. El‐Deiry2, Jason R. Parks3, Kristin Higgins4, Nabil F. Saba5
1Assistant Professor, Department of Hematology Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
2Associate Professor, Department of Otolaryngology, Winship Cancer Institute of Emory University, Atlanta, GA
3Resident, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
4Assistant Professor, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
5Professor and Director of the Head and Neck Medical Oncology Program, Department of Hematology Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

Tóm tắt

AbstractAnswer questions and earn CME/CNELaryngeal cancer remains one of the most common tumors of the respiratory tract. Fortunately, significant advancements have been made over the past decade in the treatment of laryngeal cancer. Although surgery has been the historical mainstay for localized disease and still is an integral part of treatment, nonsurgical options like radiation and systemic therapy have emerged as viable options. In addition, in the metastatic setting, novel agents are showing promise for this patient population. The care for patients with laryngeal cancer continues to evolve and truly requires a multidisciplinary team‐based approach. Unique morbidities, such as loss of natural voice, respiration, and airway protection during swallowing, are observed with this disease and require special consideration. CA Cancer J Clin 2017;67:31–50. © 2016 American Cancer Society.

Từ khóa


Tài liệu tham khảo

10.3322/caac.21332

10.1634/theoncologist.7-suppl_4-2

10.1002/hed.20710

10.1002/lary.25212

10.3322/caac.21173

10.1200/JCO.2003.10.106

10.1093/oxfordjournals.epirev.a036223

10.1046/j.1365-2796.2002.01022.x

10.1016/S1470-2045(06)70577-0

10.1038/sj.bjc.6600469

10.1016/S0140-6736(73)92275-7

10.1097/JOM.0b013e31823c1343

10.1093/annonc/mdt392

10.1016/j.oraloncology.2008.02.011

10.3109/00016489.2014.927592

Galli J, 2006, Laryngeal carcinoma and laryngo‐pharyngeal reflux disease, Acta Otorhinolaryngol Ital., 26, 260

10.1002/lary.25738

10.1016/S1470-2045(14)70471-1

10.1038/modpathol.2012.159

10.1038/bjc.2015.59

10.1200/JCO.2013.54.5228

10.1016/j.otc.2008.01.016

10.1148/radiol.2492072183

10.1097/MLG.0b013e31805d017b

10.1016/j.prro.2011.03.003

10.1002/1097-0142(19940515)73:10<2648::AID-CNCR2820731029>3.0.CO;2-D

10.1002/cncr.26130

10.1016/j.otc.2015.04.002

Laccourreye O, 2000, Organ Preservation Surgery for Laryngeal Cancer, 73

10.1016/j.otc.2015.04.007

10.1177/000348948509400607

10.1002/1097-0142(19880601)61:11<2260::AID-CNCR2820611121>3.0.CO;2-C

10.1007/s004050050228

10.1001/jamaoto.2013.4990

10.1007/s00405-002-0478-6

10.1177/000348940611500803

10.1007/s00405-003-0697-5

10.1001/archotol.134.9.965

10.1016/j.jvoice.2014.12.005

10.1056/NEJM199106133242402

10.1056/NEJMoa031317

10.1097/01.mlg.0000236095.97947.26

Dziegielewski PT, 2012, Primary total laryngectomy versus organ preservation for T3/T4a laryngeal cancer: a population‐based analysis of survival, J Otolaryngol Head Neck Surg., 41, S56

10.1016/j.ijrobp.2015.03.004

10.1001/archotol.133.12.1270

10.1200/JCO.2015.61.2978

10.1016/j.oraloncology.2012.11.002

10.1002/lary.20294

10.1002/hed.10069

Wang CC, 1991, Deciding on optimal management of supraglottic carcinoma, Oncology (Williston Park)., 5, 41

10.1016/S1470-2045(10)70290-4

10.1001/archotol.133.12.1198

10.1016/S0140-6736(06)69121-6

10.1002/1097-0347(200007)22:4<380::AID-HED11>3.0.CO;2-E

10.1016/S0360-3016(97)00284-8

10.1016/j.ijrobp.2005.06.014

10.1016/j.ijrobp.2014.04.041

10.1016/S0360-3016(02)03938-X

10.1002/hed.20279

10.1038/sj.bjc.6690420

10.1097/00005537-199902000-00014

10.1007/s00520-011-1146-4

10.1177/000348941212100902

10.1056/NEJM198110223051704

10.1016/0360-3016(83)90292-4

10.1093/jnci/88.13.890

10.1200/JCO.2012.43.6097

10.1002/hed.21294

10.1200/JCO.2012.43.6097

10.1200/JCO.2007.14.8841

10.1001/jamaoto.2016.1228

10.1001/jamaoto.2016.1229

10.1200/JCO.2012.42.3988

10.1016/j.oraloncology.2012.06.014

10.1056/NEJMoa071028

10.1056/NEJMoa070956

10.1093/annonc/mdn752

10.1016/j.radonc.2009.04.014

10.1016/j.radonc.2011.05.036

10.1016/S1470-2045(13)70011-1

10.1200/JCO.2013.54.6309

10.1056/NEJMoa053422

10.1200/JCO.2015.63.1671

10.1200/JCO.2013.53.5633

10.1016/j.oraloncology.2014.06.014

Thawley SE, 1999, Comprehensive Management of Head and Neck Tumors

10.1001/archotol.129.1.44

10.1002/hed.24355

10.1177/0194599813486257

10.1001/jamaoto.2013.3995

10.1002/lary.24138

10.1111/coa.12309

10.1002/hed.23145

10.1002/lary.24005

10.1177/0194599811432264

10.1002/lary.24796

10.1016/j.otohns.2009.03.024

10.1001/archoto.2009.126

10.3109/00016489.2012.672768

10.1002/lary.24619

10.1001/jamaoto.2013.2761

10.1055/s-0034-1395417

10.1002/cncr.24947

10.1002/lary.22477

10.1097/00005537-200105000-00010

10.1002/jso.20483

10.1001/archotol.128.12.1384

10.1016/j.otohns.2008.03.024

10.1002/lary.23785

10.1097/00005537-200105000-00031

10.1001/archotol.1997.01900050039004

10.1016/j.otc.2015.04.013

10.1002/hed.20697

10.1200/JCO.2006.07.9194

10.1016/j.ijrobp.2014.11.023

10.1097/COC.0b013e3181aacba5

10.1200/JCO.2015.62.0963

10.1007/BF00263902

10.1038/bjc.1990.59

10.1200/JCO.1992.10.2.257

10.1002/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q

10.1200/JCO.2005.01.057

10.1200/JCO.2006.06.7447

10.1056/NEJMoa0802656

National Cancer Institute.Chemotherapy with or without bevacizumab in treating patients with recurrent or metastatic head and neck cancer.clinicaltrials.gov/ct2/show/NCT00588770. Accessed August 16 2016.

10.1200/JCO.2015.61.1509

10.1056/NEJMoa1507643

10.1056/NEJMoa1504030

10.1016/S1470-2045(16)30066-3

GillisonML.Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate 141 [Abstract CT098]. Paper presented at: American Association for Cancer Research (AACR) Annual Meeting 2016; April 16–20 2016; New Orleans LA.

10.1038/nature14129

10.1158/1535-7163.MCT-13-1093

10.1158/1078-0432.CCR-16-0558

10.1016/j.athoracsur.2009.04.040

10.1111/coa.12348

10.1007/s00268-003-7107-4

10.1002/hed.24322

Thông tin
Thông tin xuất bản

Ca-A Cancer Journal for Clinicians

Tập 67 Số 1

31-50

Thông tin tác giả